Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedixTSE:331A -1.40%19 EBITDA Margin % is 20.12% as of Mar. 2026, which is 8% above its 10-year median of 18.56. GuruFocus rates TSE:331A with a GF Score™ of 19/100. The stock has 4 warning signs investors should review. Among 1,009 Media - Diversified companies, Medix ranks better than 71.36% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Medix's EBITDA for the
six
months ended in Mar. 2026 was 円467 Mil. Medix's Revenue for the
six
months ended in Mar. 2026 was 円2,320 Mil. Therefore, Medix's EBITDA margin for the quarter that ended in Mar. 2026 was 20.12%.
Medix (TSE:331A) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Medix EBITDA Margin % Related Terms
Medix EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Medix's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:331A vs APP, OMC, TTD: EBITDA Margin % Comparison
For the Advertising Agencies subindustry, Medix's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medix EBITDA Margin % vs Media - Diversified Industry
For the Media - Diversified industry and Communication Services sector, Medix's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Medix's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medix (TSE:331A) has a EBITDA Margin % of 20.12% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medix and its competitors. This is near median its historical median of 18.56. Over the past decade, Medix's EBITDA Margin % has ranged from 16.66 to 24.02. According to the industry distribution chart, Medix ranks #289 out of 1009 companies in the Media - Diversified industry, placing it in the top 28.6%.
Is Medix's EBITDA Margin % too high?
Medix's current EBITDA Margin % of 20.12% is near median its 10-year median of 18.56. Over the past 10 years, this metric has ranged from a low of 16.66 to a high of 24.02. The Media - Diversified industry median EBITDA Margin % is 8.16. Medix's value of 20.12% is 146.6% above this industry median. Based on the distribution chart, Medix ranks #289 out of 1009 companies in the Media - Diversified industry, which is above the industry midpoint. Overall, Medix has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Medix's EBITDA Margin % compare to APP and OMC?
According to the Media - Diversified industry distribution chart, Medix ranks #289 out of 1009 companies for EBITDA Margin %. This puts Medix in the upper half of its industry. The industry median EBITDA Margin % is 8.16. Medix's value of 20.12% is 146.6% above this benchmark. Historically, Medix's own EBITDA Margin % has ranged from 16.66 to 24.02 over the past decade. While the company's 10-year median is 18.56 vs. the industry median of 8.16, Medix has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Media - Diversified company?
The median EBITDA Margin % among Media - Diversified companies is 8.16, based on 1,009 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medix's current EBITDA Margin % of 20.12% is 146.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Medix and its competitors. For the Media - Diversified industry, the median EBITDA Margin % is 8.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medix's current EBITDA Margin % is 20.12%, which is near median its own 10-year median of 18.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medix stock overvalued right now?
Medix (TSE:331A) has a current EBITDA Margin % of 20.12%. The current EBITDA Margin % is 20.12%, which is near median its 10-year median of 18.56 and 146.6% above the Media - Diversified industry median of 8.16. Medix's overall GF Score™ is 19/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Medix (TSE:331A), the current EBITDA Margin % is 20.12% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Medix Inc is an internet advertising agency that places the utmost importance on understanding its clients' business models deeply and helping them solve problems over the medium to long term. It is engaged in Digital marketing services including creative design and production, data parsing and analysis, and Internet advertising services. The company provides services in the digital marketing field to clients in various lines and industries.
19GF Score
Get the complete analysis for TSE:331A
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:331A has been successfully added to your 
